发明名称 |
Transmembrane nfat inhibitory peptide |
摘要 |
The present invention aims to solve the conventional problems by providing a peptide compound, in which when administered to a patient of immunologic disease, cardiac hypertrophy or a disease caused by NFAT activation, the period from administration to actual exhibition of effectiveness is short and there are no side effects or antigenicity. Specifically, the present invention relates to a membrane permeable NFAT inhibitory peptide comprising several consecutive arginines and a NFAT-activity inhibitory peptide sequence; a NFAT activation inhibitory agent comprising the peptide; and a immunosuppressive agent and cardiac hypertrophy suppressive agent, comprising the peptide compound as the active ingredient.
|
申请公布号 |
US7160863(B2) |
申请公布日期 |
2007.01.09 |
申请号 |
US20040504333 |
申请日期 |
2004.08.25 |
申请人 |
JAPAN SCIENCE AND TECHNOLOGY AGENCY |
发明人 |
MATSUI HIDEKI;MATSUSHITA MASAYUKI |
分类号 |
A61K38/00;A61K38/16;A61P9/00;A61P37/02;A61P37/06;A61P43/00;C07K2/00;C07K7/08;C07K14/00;C07K14/47 |
主分类号 |
A61K38/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|